Abpro Holdings, Inc. (NASDAQ: ABP)

Sector: Healthcare Industry: Biotechnology CIK: 0001893219
Market Cap 931,923.60
P/B -0.06
P/E -0.04
P/S 0.00
ROIC (Qtr) 59.65
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 147,000.00
Debt/Equity (Qtr) -0.01
Add ratio to table...

About

Atlantic Coastal Acquisition Corp. II (ACAB) operates as a blank check company, incorporated in Delaware in May 2021. The company is focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. ACAB's assets primarily consist of cash, with no operations at the moment. The company generates revenue through the sale of its units, which consist of one share of Series A common stock and one-half of one public warrant. The units were sold at a price...

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 343000 provide 2.33x coverage of short-term debt 147000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 1.53M provides 10.44x coverage of total debt 147000, indicating robust asset backing and low credit risk.
  • Retained earnings of (124.63M) represent substantial 7.72x of equity (16.14M), indicating strong internal capital generation.
  • Strong tangible asset base of 1.53M provides 9.08x coverage of intangibles 169000, indicating robust asset quality.
  • R&D investment of 1.40M represents significant 5.15x of receivables 271000, indicating innovation-driven growth.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 1.40M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (9.20M) shows concerning coverage of stock compensation expenses of 1.55M, with a -5.92 ratio indicating potential earnings quality issues.
  • Operating earnings of (10.68M) show weak coverage of depreciation charges of 583000, with a -18.32 ratio indicating high capital intensity and potential reinvestment needs.
  • Cash position of 343000 provides weak coverage of payables of 4.72M, which is 0.07x, indicating potential working capital stress and supplier relationship risks.
  • Operating cash flow of (9.20M) is outpaced by equity issuance of 11.10M (-0.83 ratio), indicating concerning reliance on equity markets for funding operations.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.66 11.06
EV to Cash from Ops. EV/CFO -0.12 26.32
EV to Debt EV to Debt 7.67 762.61
EV to EBIT EV/EBIT -0.11 -13.49
EV to EBITDA EV/EBITDA -0.13 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.12 25.66
EV to Market Cap EV to Market Cap 1.21 203.37
EV to Revenue EV/Rev 0.00 156.31
Price to Book Value [P/B] P/B -0.06 20.59
Price to Earnings [P/E] P/E -0.04 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) -2.17 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) -9.01 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 143.26 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -44.28 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 16.51 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -44.28 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -53.75 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -3,478.57 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -23.45 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.02 3.92
Current Ratio Curr Ratio (Qtr) 0.07 7.33
Debt to Equity Ratio Debt/Equity (Qtr) -0.01 0.48
Interest Cover Ratio Int Coverage (Qtr) -9.01 956.66
Times Interest Earned Times Interest Earned (Qtr) -9.01 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 0.00 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) 0.00 -18,246.34
EBT Margin % EBT Margin % (Qtr) 0.00 -19,108.08
Gross Margin % Gross Margin % (Qtr) 0.00 -10.30
Net Profit Margin % Net Margin % (Qtr) 0.00 -19,056.96